Indications   

It can stimulate the body to produce immunity against hepatitis E virus for the prevention of hepatitis E.

Highlights

1. The first Hepatitis E vaccine in the world , launched in 2012

2. 100% protection rate and good safety had been proven in large-scale phase III clinical trial(> 110000 subjects)

3. It’s predicted that immune persistence can last >10 years

4. Complete phase I, II, III clinical trial conducted in China

5. Being registered in India, Thailand, Nepal, Pakistan.

Specification

Each 0.5 ml dose contains 30μg of purified recombinant hepatitis E virus antigen.

Dosage Form

Solution for Injection

Package

1 ml/ 1 pre-filled syringe/ 1 box

Route of Administration

 Intramuscular injection

Immunization schedule 

3 doses of intramuscular injection following the 0, 1months, 6 months schedule

Target population

 Age> 16 years

Shelf life 

36 months